Tirzepatide
Hypoglycaemic excluding Insulin · GLP-1 receptor agonist
Indications
Used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Dosage
INJECTION: SC: Adults: Initially 2.5 mg once weekly. After 4 wks, increase to 5 mg once weekly. If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose. Children: Not recommended.
Administration
Administer once weekly at any time of day, with or without meals. Inject subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites with each dose. Inspect Tirzepatide visually before use. It should appear clear and colorless to slightly yellow. Do not use if particulate matter or discoloration is seen. When using with insulin, administer as separate injections and never mix. It is acceptable to inject Tirzepatide and insulin in the same body region, but the injections should not be adjacent to each other. Stability: Store in a refrigerator at 2-8°C. If needed, each single-dose pen can be stored unrefrigerated at temperatures not to exceed 30°C for up to 21 days. Do not freeze Tirzepatide. Do not use Tirzepatide if frozen. Store in the original carton to protect from light.
Adverse Effects
Nausea, diarrhoea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain.
Risk Factor (Pregnancy/Lactation)
Pregnancy: Contraindicated in pregnancy. Lactation: Caution advised or effect undetermined. Contraindications: Type-1 diabetes mellitus. Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2. Precautions: Acute kidney injury: Monitor renal function in patients with renal impairment reporting severe adverse gastrointestinal reactions. Monitor patients with a history of diabetic retinopathy for progression. Pancreatitis.
Interactions
Insulin secretagogue (e.g. sulfonylurea). Insulin. Warfarin. Oral medications.
Advice to Patient
Females of reproductive potential using oral contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation. If a dose is missed, administer as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, resume regular once weekly dosing schedule. The day of weekly administration can be changed, if necessary, as long as the time between the two doses is at least 3 days (72 hours). Report if any of the following symptoms occur: a lump in the neck, persistent hoarseness, dysphagia, or dyspnoea, severe abdominal pain that may radiate to the back, and which may or may not be accompanied by vomiting, signs and symptoms of hypoglycaemia, signs and…
Pharmacokinetics
Bioavailability: 80%. Metabolism: Via proteolytic cleavage of the peptide backbone, beta-oxidation of the C20 fatty diacid moiety and amide hydrolysis. Half-life elimination: Approx. 5 days. Time to peak, plasma: 8-72 hrs. Excretion: Urine and faeces.
Brands with this active ingredient
Compiled by Healify Pharmacy from published drug references. How we compile it →
Always consult a pharmacist or doctor.